Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covis Pharmaceuticals has announced the availability of Zantac (ranitidine hydrochloride) injection for therapeutic use throughout the US and Puerto Rico.
Subscribe to our email newsletter
Covis will market and distribute Zantac Injection in three SKUs, including 2mL, 6mL and 40ml vials, and expects to launch the product in 50mg premixed bags, shortly.
The histamine H2-receptor antagonist is indicated for the treatment of some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers or as an alternative to the oral dosage form for short-term use.
Covis CEO Bill Collins said by making Zantac Injection available again, the company has responded to current needs.
"Covis can invest the necessary work and focused expertise to reduce distribution interruptions for critical therapies," Collins added.